Briefing
Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval (Draft Guidance for Industry)
Draft guidance, posted on the FDA site on January 20, 2026 (Federal Register notice January 21, 2026). Recommends MRD-negativity rate (in patients who have achieved CR or stringent CR), assessed in bone marrow by flow or sequencing, and CR rate as primary endpoints to support accelerated approval. MRD negativity should be assessed at a threshold of at least 1 in 10^5 residual tumor cells; alternate thresholds require justification. Verification of clinical benefit (typically PFS or OS) will generally be required, and confirmatory trial(s) should generally be underway prior to accelerated approval. Comments were due March 23, 2026.
- Design: regulatory
- Assay: Bone-marrow flow cytometry or sequencing; threshold of at least 1 in 10^5